MUNICH & SYDNEY - TelAve -- OncoBeta® GmbH, a commercial stage medical device company specialized in innovative epidermal radioisotope therapies. And GenesisCare, the largest provider of cancer care in Australia, the UK and Spain are excited to announce a partnership to provide an innovative, non-invasive, single-session treatment for non-melanoma skin cancer. OncoBeta and GenesisCare have recently completed recruitment of a phase 4 clinical trial and are now expanding access to suitable skin cancer patients.

Starting in June 2023 GenesisCare will offer the new therapy from their Tugan clinic, at John Flynn Private Hospital Gold Coast. This will be followed shortly after by GenesisCare clinics at Murdoch at St John of God Hospital – Perth, Chermside Medical Complex – Brisbane, Hurstville at Waratah Private Hospital – Sydney, and Cabrini Hospital – Melbourne.

Australia has the highest incidence of non-melanoma skin cancer in the world, with 32% of Australians treated for non-melanoma skin cancer each year. Recent data indicated that 70% of Australians will have at least one non-melanoma skin cancer excised. People with a history of skin cancer have a greatly elevated risk of developing new lesions. Currently used standard of care surgical treatment options can be scarring and disfiguring. OncoBeta's technology will offer a new and effective treatment option to address this large Australian medical burden.

Nicholas H. Vetter, OncoBeta Group CEO, stated "This is a huge step forward for our organization. We are very excited about working together with GenesisCare to bring our technology for treating non-melanoma skin cancer to Australia. GenesisCare is a strong partner we look forward to collaborating with to reach thousands of Australians afflicted with non-melanoma skin cancer."

More on TelAve News

• ScreenPoints Puts Film Investors in the Credits—and in the Money With New FinTech Platform
• Pathways to Adulthood Conference May 17 at Melville Marriott Honoring NYS Assembly Member Jodi Giglio, Suffolk County Legislator Nick Caracappa
• Adster Techologies awarded US Patent for breakthrough innovation in reducing latency in Ad Serving
• Robert Fabbio Inducted into the Austin Technology Council Hall of Fame
• Cybersecurity is Protecting Your Personal Information and Your Portfolio

"The partnership with GenesisCare is a significant milestone for OncoBeta in Australia" said Shannon D. Brown III, CEO and Managing Director at OncoBeta® GmbH "This will enhance access to precise, individualised treatments for non-melanoma skin cancer patients. The partnership aligns with our company's vision to improve quality of life for non-melanoma skin cancer patients across Australia".

GenesisCare Chief Medical Officer, Dr Marie Burke, stated "We are looking forward to Australian patients having access to OncoBeta's innovative treatment for non-melanoma skin cancers. This fits well into the treatment portfolio offered at GenesisCare sites and represents a promising new option for certain patients with skin cancer that may be suitable for the single-session, non-invasive treatment".

Always talk to your doctor about what treatment options are suitable for you.

Healthcare Professionals can contact GenesisCare or OncoBeta for more information.

About GenesisCare
GenesisCare is a global healthcare company and one of the world's largest integrated oncology organisations. The company's purpose is to design care experiences that get the best possible life outcomes. This is grounded in the belief that care should be focused on the individual, not the condition.

GenesisCare is the world's largest provider of radiotherapy – a vital treatment option for cancer patients – and provides patients with access to diagnostics, medical oncology, surgical oncology, radiotherapy, and novel therapies alongside the ability to participate in the latest clinical trials. With a growing research and trials program numbering more than 150 clinical trials, a contract research organisation, and global innovation programs focused on precision medicine and novel therapies, GenesisCare aims to bring new therapies to more patients in need in a more affordable way.

More on TelAve News

• L2 Aviation Celebrates Grand Opening of New Facility at Cincinnati/Northern Kentucky International Airport (CVG)
• Managing Summer Staffing Surges with Confidence: Why Name Badges Are a Must for Seasonal Success
• Visa Named Title Sponsor of Ascending Athletes' Business Owners Summits for NFL Entrepreneurs
• The Paris Court of International Arbitration Elects Dr. John J. Maalouf as its New President
• Whistleblower Seeks SEC and Shareholder Review of Cogent Communications' 2003 Acquisition of FNSI

Every year, GenesisCare clinical teams see more than 450,000 people across 350+ locations, including more than 300 locations in the U.S., 40 in Australia, 14 in the UK, and 18 in Spain. Headquartered in Sydney, Australia, the organisation employs more than 5,500 highly trained physicians, healthcare professionals and support staff across Australia, Europe, and the U.S.

For more information visit www.genesiscare.com/au

About OncoBeta® GmbH
OncoBeta®, with its headquarters located in Garching near Munich, Germany, is a privately held medical device company, specializing in the development and commercialization of state-of-the-art, innovative therapies. Since its foundation, OncoBeta has concentrated its efforts on the development, regulatory approval(s) and commercialization of the epidermal radioisotope therapy Rhenium-SCT® (Skin Cancer Therapy), targeting NMSCs. OncoBeta has perfected the customized application and device management system in conformity with all health, safety and environmental protection regulatory standards.

Find out more at www.oncobeta.com

Follow us on social media:
LinkedIn: https://www.linkedin.com/company/oncobeta-gmbh/
Facebook: https://www.facebook.com/oncobeta/

Forward-looking statements
This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of OncoBeta's control, and which could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning OncoBeta's plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. OncoBeta® undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law. Obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.